Compare Crispr Therapeutics AG (CRSP) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Flux Power Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Flux Power Holdings Inc trades at $0.47 (market cap $9.97M). The key difference: Crispr Therapeutics AG is far larger — about 489.5× Flux Power Holdings Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Flux Power Holdings Inc for 20 Days on average.
| CRSP | FLUX | |
|---|---|---|
Market Cap | $4.88B | $9.97M |
Volume | 2,861,747 | 817,320 |
Sector | Health | Industrials |
52-Week High | $74.92 | $6.66 |
52-Week Low | $44.34 | $0.41 |
Typical Hold Time | 77 Days | 20 Days |
Enterprise Value | $3.30B | $18.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
FLUX trades at $0.47, down 3.96% today, with bearish technical signals from moving averages. The company reported Q4 2026 revenue of $8.2M, beating expectations, but posted a net loss of $6.67M for 2025. Recent news highlights a rejected acquisition proposal from Solidion Technology. Despite negative profitability metrics, all six covering analysts maintain Buy ratings.
FLUX faces significant execution risks with negative margins and cash flow challenges, but analyst consensus remains bullish. The stock's current valuation at 0.22 P/S suggests potential upside if operational improvements materialize. Key risks include sustained losses and competitive pressures in the energy storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
